Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing
- 1 January 1994
- Vol. 12 (12) , 1090-1096
- https://doi.org/10.1016/0264-410x(94)90178-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant.Journal of Clinical Investigation, 1992
- Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virusBiochemical and Biophysical Research Communications, 1992
- Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine)Vaccine, 1991
- Vaccine-induced escape mutant of hepatitis B virusThe Lancet, 1990
- Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine)Vaccine, 1990
- Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterizationJournal of Biotechnology, 1988
- Synthesis in yeast of hepatitis B virus surface antigen modified P31 particles by gene modificationBiochemical and Biophysical Research Communications, 1986
- Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus-neutralizingVaccine, 1986
- HEPATITIS B VACCINE WITH AND WITHOUT POLYMERISED ALBUMIN RECEPTORSThe Lancet, 1985
- Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNAPublished by American Medical Association (AMA) ,1984